EU agency investigating reports on blood clots from use of Janssen vaccine

This news has been read 18454 times!

BRUSSELS, April 14 (KUNA) — The European Medicines Agency (EMA) announced Wednesday that its safety committee is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen’s COVID-19 vaccine. US health and disease control bodies recommended yesterday that the use of the vaccine should be paused while they review six reported cases in the United States. More than 6.8 million doses of the vaccine have been administered, said the EMA based in Amsterdam in a press release.

Janssen has announced their decision to delay the rollout of the vaccine in the EU while investigations continue. The vaccine was authorised in the EU on 11 March 2021 but widespread use of the vaccine within the EU has not yet started.
EMA said it is investigating all the cases reported and will decide whether regulatory action is necessary.


While its review is ongoing, EMA said it remains of the view that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects. COVID-19 Vaccine Janssen is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. The most common side effects with COVID-19 Vaccine Janssen are usually mild or moderate and get better within one or two days after vaccination, it noted.

This news has been read 18454 times!

Related Articles

Back to top button

Advt Blocker Detected

Kindly disable the Ad blocker

Verified by MonsterInsights